21 April 2026 - A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.

NICE has recommended zanidatamab (Ziihera, Jazz Pharmaceuticals), in final draft guidance for adults with HER2 positive advanced biliary tract cancer - a group of cancers affecting parts of the body that store and transport bile, including the bile ducts and gallbladder, who have already received at least one treatment.

Read NICE press release